论文部分内容阅读
面对非生物抗风湿药物(DMARDs)无效或疗效减退,幼年特发性关节炎(JIA)患儿迫切需要新的治疗方法。目前已应用于JIA治疗的生物制剂主要包括:针对参与免疫炎性反应重要致炎因子(如TNF-α、IL-1、IL-6等)的抗体;针对参与免疫应答信号分子[如细胞素性T淋巴细胞相关抗原4(CTLA-4)]的抗体;针对重要免疫细胞(如B淋巴细胞)的抗体。生物制剂的问世为JIA的治疗提供了新的希望。
Faced with ineffective or curative effects of non-biological anti-rheumatic drugs (DMARDs), there is an urgent need for new treatments in children with juvenile idiopathic arthritis (JIA). At present, the biological agents that have been used in the treatment of JIA mainly include: antibodies directed against inflammatory cytokines (such as TNF-α, IL-1 and IL-6) involved in immune and inflammatory responses; T lymphocyte associated antigen 4 (CTLA-4)]; antibodies against important immune cells (such as B lymphocytes). The advent of biologics offers new hope for the treatment of JIA.